Cogent Biosciences, Inc. balance sheet COGT

Annual Quarterly

As of Jun 30, 2026, Cogent Biosciences, Inc. had total assets of $834.5 million and total liabilities of $302.2 million. Total assets were up 203.7% from a year earlier. Stockholders' equity was $532.4 million. It held $792.3 million in cash and investments against $244.3 million of total debt, net cash of $548.0 million. The current ratio, current assets divided by current liabilities, was 13.57.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
Assets
Cash
181
+42.0%
312
+217.8%
98
+84.4%
53
-61.9%
140
-36.3%
220
-9.3%
242
+547.2%
37
-32.8%
56
Short-term investments
611
+454.3%
589
+211.7%
189
-11.1%
212
+78.0%
119
—
—
—
23
Long-term investments
—
—
—
7
—
—
—
—
—
Cash and investments
792
+233.1%
901
+205.8%
287
+8.0%
273
+5.4%
259
+18.0%
220
-9.3%
242
+301.3%
37
-32.8%
79
Receivables
—
—
—
—
—
—
—
2
+19.9%
2
Total current assets
805
+228.5%
910
+207.1%
296
+9.5%
271
+2.2%
265
+19.0%
223
-9.1%
245
+503.4%
41
-49.9%
81
Property and equipment, net
5
-18.4%
5
-15.6%
6
-22.5%
8
+7.2%
8
+356.2%
2
+1173.1%
0
-92.8%
2
-42.6%
3
Total assets
835
+203.7%
938
+185.9%
328
+4.6%
313
+4.2%
301
+29.6%
232
-7.5%
251
+407.7%
49
-42.5%
86
Liabilities and equity
Accounts payable
7
-55.0%
10
-20.9%
12
+12.7%
11
+82.4%
6
+67.7%
3
+375.8%
1
-77.0%
3
+109.5%
2
Total current liabilities
59
+1.5%
64
+14.8%
56
+46.0%
38
+42.2%
27
+57.2%
17
+30.4%
13
-1.2%
13
-46.9%
25
Total liabilities
302
+152.3%
301
+320.7%
72
+28.7%
56
+23.4%
45
+151.7%
18
+10.2%
16
-8.0%
18
-31.3%
26
Stockholders' equity
532
+243.4%
636
+148.3%
256
-0.6%
258
+0.8%
256
+19.4%
214
-8.7%
235
+638.8%
32
-47.3%
60
Debt
Long-term debt
223
+408.4%
223
—
—
—
—
—
—
—
Lease liabilities
21
+24.5%
16
-9.0%
17
-7.4%
19
-4.1%
20
+522.8%
3
-39.4%
5
-13.7%
6
—
Total debt
244
+302.7%
239
+1267.1%
17
-7.4%
19
-4.1%
20
+522.8%
3
-39.4%
5
-13.7%
6
—
Net cash
548
+209.3%
662
+138.9%
270
+9.2%
254
+6.1%
240
+10.7%
217
-8.6%
237
+336.3%
31
—
Ratios
Current ratio
13.57x
14.23x
5.32x
7.09x
9.87x
13.04x
18.70x
3.06x
3.25x
Debt to equity
0.46x
0.38x
0.07x
0.07x
0.08x
0.01x
0.02x
0.19x
—
Return on equity
-70.85%
-51.69%
-99.83%
-74.63%
-54.84%
-33.74%
-31.88%
-100.22%
-57.33%
Return on assets
-45.20%
-35.08%
-78.03%
-61.39%
-46.62%
-31.14%
-29.81%
-64.41%
-40.19%
Book value per share
3.10
3.95
2.32
2.99
3.66
4.89
7.25
4.14
2.00
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
COGT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
Large accelerated filer
SEC CIK
1622229
Former names
Unum Therapeutics Inc. (until Oct 5, 2020); Unum Therapeutics, Inc. (until Mar 30, 2018)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.